{"ticker": {"uuid": "a5811d0c-90e3-47b1-99f5-212e4dd53af6", "symbol": "CBIO", "name": "Crescent Biopharma, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Fairmount Funds holds 16.5% of Crescent Biopharma (CBIO) after July 2026 deal", "summary": "Fairmount Funds Management LLC and its affiliates, including Fairmount Healthcare Fund II L.P., now beneficially own 16.50% of Crescent Biopharma (CBIO), totaling 6,593,385 Ordinary Shares as of July 16, 2026. This increased stake follows the purchase of 853,450 Ordinary Shares a", "url": "https://www.stocktitan.net/sec-filings/CBIO/schedule-13d-a-crescent-biopharma-inc-amended-major-shareholder-repor-643066df58e0.html", "source_name": "Stock Titan", "published_at": "2026-07-21T07:41:01", "published_display": "21 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fairmount Healthcare Fund II LP acquires 853,450 Crescent Biopharma shares for $12.38 million", "summary": "Fairmount Healthcare Fund II LP has acquired 853,450 ordinary shares of Crescent Biopharma at $14.5 each, increasing its total stake to 3,601,316 shares. Additionally, the fund purchased 525,897 pre-funded warrants at the same price, bringing its warrant position to 2,294,037. To", "url": "https://www.bitget.com/amp/news/detail/12560605521763", "source_name": "Bitget", "published_at": "2026-07-21T02:09:44", "published_display": "21 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fairmount Funds' $12 Million Bet on Crescent Biopharma: A Strong Signal Amidst Volatility", "summary": "Fairmount Funds Management, a major stakeholder and director of Crescent Biopharma (CBIO), recently invested over", "url": "https://www.kavout.com/market-lens/fairmount-funds-12-million-bet-on-crescent-biopharma-a-strong-signal-amidst-volatility", "source_name": "Kavout | AI", "published_at": "2026-07-21T00:09:44", "published_display": "21 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider fund at Crescent Biopharma (NASDAQ: CBIO) buys 1.38M shares, warrants", "summary": "Fairmount Healthcare Fund II L.P., an entity linked to Crescent Biopharma (NASDAQ: CBIO), recently acquired 853,450 ordinary shares and 525,897 pre-funded warrants, totaling 1.38 million share equivalents. These transactions, executed on July 16, 2026, increased Fairmount's indir", "url": "https://www.stocktitan.net/sec-filings/CBIO/form-4-crescent-biopharma-inc-insider-trading-activity-86eeba4f21b9.html", "source_name": "Stock Titan", "published_at": "2026-07-20T21:41:01", "published_display": "20 Jul 2026 21:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgJBVV95cUxPRHNDSHFfV2xSMEE1Q01ZRm5DUGhtQ1hXanpEVTNUVThZWW5IRXd3VDJ0VlEwZHNTdmlmb0JUYVRYa0JUOVpOTjJ0dGlSdVE3dFdSNkhQeUZkYkRLYXJfY2dFNTBJUEs4MEwtYzFlRGp6a1pSeG1ldjhQOVFQVTZaTk9FRTd2SFN4akFXeWRqbFB3X25EYWVSOUFtSHduN1RBdnNGcHhNNl9LYkFSb1dpMUNNYWhVZ3VZQmYwV0dNMVhxellicU5BSktudkJJMGQwbkxvSVdhbnB2U3M1VnB3TGJUTmIyM081UEtrclJMaGhpRUdVck4yTFlWcVpHUGxHT2dBV3RXVFNmZEpQMVlFZ0hnZk1YeHhRWUFlYk5zMURCam5vcHc?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-17T10:42:00+00:00", "published_display": "17 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (CBIO) Jefferies Global Healthcare Conference 2026 Summary", "summary": "Crescent Biopharma (CBIO) presented at the Jefferies Global Healthcare Conference 2026, highlighting strong clinical data for HARMONi-6, validating PD-1/VEGF bispecifics, and discussing critical trial design strategies. The company provided updates on its pipeline, focusing on CR", "url": "https://quartr.com/events/crescent-biopharma-inc-cbio-jefferies-global-healthcare-conference-2026_FVuhh8IK", "source_name": "Quartr", "published_at": "2026-07-17T09:40:02", "published_display": "17 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares", "summary": "Crescent Biopharma has announced the closing of its public offering, which included 3,000,000 ordinary shares and pre-funded warrants to purchase 3,450,000 ordinary shares, at a price of $4.00 per share or $3.9999 per pre-funded warrant. The offering also saw the full exercise of", "url": "https://www.moomoo.com/news/post/73095343/press-release-crescent-biopharma-announces-closing-of-public-offering-of?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-17T03:40:02", "published_display": "17 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma closes $143.7 million public offering By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOZWhCRUNFOGlhdWdjaEgxZldUeVNYaWlCSTVyMUN0VVNfR3c2SVNFTWJpRTdkV3VwcmxWSUJNN0RXZEx5eXFraF9VSDJ0eU5admdicjdsUTZ4OGxxRDdKaEVLVnNZcVRjZUM0S0FPMkFSQ2FVU21NWU1aQnFnS29FN3dmLXNHMmg5MEdqYVRJM1BEb2ppdGJDY2RRR1laU1RUYWs4bHJZUDZuQ0ZjcS0yT1A0b3VJZw?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-17T00:12:58+00:00", "published_display": "17 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Closes $143.7 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/crescent-biopharma-closes-143-7-202247362.html", "source_name": "MT Newswires", "published_at": "2026-07-16T20:22:47+00:00", "published_display": "16 Jul 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (CBIO) Proxy filing Summary", "summary": "Crescent Biopharma (CBIO) has released a summary of its proxy filing ahead of its Annual General Meeting on June 2, 2026. Key proposals include the election of two Class II directors, ratification of PricewaterhouseCoopers LLP as auditor, and advisory votes on executive compensat", "url": "https://quartr.com/events/crescent-biopharma-inc-cbio-proxy-filing_FVuhhxfq", "source_name": "Quartr", "published_at": "2026-07-16T20:10:50", "published_display": "16 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Offering Closes With 9.4M Shares, Warrants", "summary": "Crescent Biopharma (CBIO) announced the closing of its underwritten public offering, which included 9,387,896 ordinary shares and pre-funded warrants for up to 525,897 ordinary shares. The offering, priced at $14.50 per ordinary share and $14.499 per pre-funded warrant, generated", "url": "https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-closing-of-public-offering-of-ordinary-v6nqa6hv9ivn.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:10:13", "published_display": "16 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares", "summary": "Crescent Biopharma, Inc. announced the closing of its public offering, generating approximately $143.7 million in gross proceeds. The offering included 9,387,896 ordinary shares and pre-funded warrants for up to 525,897 ordinary shares, with the underwriters fully exercising thei", "url": "https://www.globenewswire.com/news-release/2026/07/16/3328781/0/en/Crescent-Biopharma-Announces-Closing-of-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T16:01:00", "published_display": "16 Jul 2026 16:01", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (CBIO) Bank of America Global Healthcare Conference 2026 Summary", "summary": "Crescent Biopharma (CBIO) presented at the Bank of America Global Healthcare Conference 2026, outlining its strategic vision in oncology with a focus on a next-gen IO bispecific (CR-001) and an ADC portfolio. The company initiated clinical dosing for CR-001 and CR-003 in early 20", "url": "https://quartr.com/events/crescent-biopharma-cbio-bank-of-america-global-healthcare-conference-2026_FVuhhoQQ", "source_name": "Quartr", "published_at": "2026-07-16T15:10:51", "published_display": "16 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 CRESCENT BIOPHARMA, INC.", "summary": "Crescent Biopharma, Inc. is offering 8,094,793 ordinary shares and 525,897 pre-funded warrants, with an aim to raise approximately $115.9 million in net proceeds to fund clinical development of its product candidates CR-001, CR-002, and CR-003, as well as for research and develop", "url": "https://www.streetinsider.com/SEC+Filings/Form+424B5+CRESCENT+BIOPHARMA%2C+INC./26774795.html", "source_name": "StreetInsider", "published_at": "2026-07-16T14:42:00", "published_display": "16 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (Nasdaq: CBIO) prices $125.0 million stock and warrant sale", "summary": "Crescent Biopharma (Nasdaq: CBIO) has priced a public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $125.0 million in gross proceeds. The offering includes 8,094,793 ordinary shares at $14.50 each and 525,897 pre-funded warrants at $14.499 eac", "url": "https://www.stocktitan.net/sec-filings/CBIO/8-k-crescent-biopharma-inc-reports-material-event-490590889f2f.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:42:00", "published_display": "15 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Prices $125 Million Public Offering of Ordinary Shares and Pre-Funded Warrants", "summary": "Crescent Biopharma announced the pricing of a public offering expected to raise approximately $125 million by selling 8,094,793 ordinary shares and 525,897 pre-funded warrants. The ordinary shares are priced at $14.50 each, and the pre-funded warrants at $14.499, with the offerin", "url": "https://www.quiverquant.com/news/Crescent+Biopharma+Prices+$125+Million+Public+Offering+of+Ordinary+Shares+and+Pre-Funded+Warrants", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T15:10:51", "published_display": "15 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Prices $125 Million Common, Warrant Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/crescent-biopharma-prices-125-million-075209963.html", "source_name": "MT Newswires", "published_at": "2026-07-15T07:52:09+00:00", "published_display": "15 Jul 2026 07:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma prices $125M public offering at $14.50/share", "summary": "Crescent Biopharma Inc. (NASDAQ:CBIO) has priced an underwritten public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $125 million. The shares are priced at $14.50, and the offering is expected to close soon, with major financial institutions ", "url": "https://www.investing.com/news/company-news/crescent-biopharma-prices-125m-public-offering-at-1450share-93CH-4792104", "source_name": "Investing.com", "published_at": "2026-07-15T04:12:52", "published_display": "15 Jul 2026 04:12", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Selling All Shares, Prefunded Warrants to Be Sold in Offering >CBIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQVS00UVBhdXNDVUxsaGs1NUhFeVFoOGMxVUJPSFJRV0dwT3lNQkpNbk5scFFoR2VTYW02bFBXdG03MFZjdzVaYy1yb3RlaHJZUUFXQ1dfRjJfekJWOHBLbzlGazY3WHZBVXF2UHZNSG1ja0dfQ1p6UDRWUXNfVG9vbzRBRlRwdlkyeEVqTEo2akVFczdNN1pTOGtHTFY2ZEtxQ0pJYXI3NGlNNFE4MGc?oc=5", "source_name": "Moomoo", "published_at": "2026-07-15T02:16:00+00:00", "published_display": "15 Jul 2026 02:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Also Offering Certain Investors Prefunded Warrants to Buy 525,897 Shares >CBIO", "summary": "Crescent Biopharma has announced an offering to certain investors of prefunded warrants to purchase 525,897 shares. This financial move allows these investors to effectively buy shares at a predetermined price in the future. The offering is likely aimed at raising capital or opti", "url": "https://www.moomoo.com/news/post/72970756/crescent-biopharma-also-offering-certain-investors-prefunded-warrants-to-buy?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-15T02:39:34", "published_display": "15 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants", "summary": "Crescent Biopharma has announced the pricing of its underwritten public offering, which includes 8,094,793 ordinary shares at $14.50 per share and pre-funded warrants for up to 525,897 ordinary shares at $14.499 per warrant. The offering is expected to generate approximately $125", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327429/0/en/Crescent-Biopharma-Announces-Pricing-of-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T01:47:56", "published_display": "15 Jul 2026 01:47", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Sets $14.50 Price for 8.1M Shares", "summary": "Crescent Biopharma (Nasdaq: CBIO) announced the pricing of an underwritten public offering of 8,094,793 ordinary shares at $14.50 per share and 525,897 pre-funded warrants at $14.499 each, expecting to raise approximately $125 million in gross proceeds. The offering is anticipate", "url": "https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-pricing-of-public-offering-of-ordinary-03p42p5b41ft.html", "source_name": "Stock Titan", "published_at": "2026-07-15T01:47:56", "published_display": "15 Jul 2026 01:47", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Launches Offering of Common Shares, Warrants", "summary": "Crescent Biopharma Inc. (NasdaqCM:CBIO) has announced an offering of common shares and warrants. This news was published on July 14, 2026, at 4:24 pm EDT. The company specializes in developing therapies for cancer patients, with lead programs including a PD-1 x VEGF bispecific an", "url": "https://www.marketscreener.com/news/crescent-biopharma-launches-offering-of-common-shares-warrants-ce7f5edddd88f524", "source_name": "marketscreener.com", "published_at": "2026-07-14T20:24:00", "published_display": "14 Jul 2026 20:24", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Crescent Biopharma, Inc. \u2013 NASDAQ:CBIO", "summary": "The article focuses on the \"Price to earnings forward\" metric for Crescent Biopharma, Inc. (NASDAQ: CBIO). It appears to be a truncated financial data page from TradingView, providing basic company and stock market information without detailed financial figures. The content prima", "url": "https://www.tradingview.com/symbols/NASDAQ-CBIO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T19:47:56", "published_display": "14 Jul 2026 19:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants", "summary": "Crescent Biopharma has announced a proposed underwritten public offering of its ordinary shares or pre-funded warrants to purchase ordinary shares. The company also intends to grant underwriters a 30-day option to purchase an additional 15% of ordinary shares. Jefferies, TD Cowen", "url": "https://www.globenewswire.com/news-release/2026/07/14/3327240/0/en/Crescent-Biopharma-Announces-Proposed-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T19:47:56", "published_display": "14 Jul 2026 19:47", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Offering Lets Investors Choose Shares or Warrants", "summary": "Crescent Biopharma (Nasdaq: CBIO) has initiated an underwritten public offering, allowing investors to purchase either ordinary shares or pre-funded warrants. The company reserves a 30-day option for underwriters to acquire an additional 15% of ordinary shares. This offering is p", "url": "https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-proposed-public-offering-of-ordinary-fy05y47xgxit.html", "source_name": "Stock Titan", "published_at": "2026-07-14T19:47:56", "published_display": "14 Jul 2026 19:47", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (NASDAQ: CBIO) reports $171.6M preliminary cash as of June 30, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxONC1tdm1PTW5HaFE1SzA1dks5bXFhbkk2ZEFrRmN5Vm4zQ3BYVG1IZXRZemhHZ2RBTTVPZlVPVk41X2x6N3ZSNUJFanFjZDVMWEFjWnZxNDJ0bVg1dWFaNndnS1AxSnp0VEdYMTVvOU9YbmJZSGExLUlxeXNlV3FLOWstaXBlUy1aR1pQci16ZkFscG1wZjdWcFM3azVPeWNHZUxMNUVtSFFXc1REU04teQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T07:00:00+00:00", "published_display": "14 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRESCENT BIOPHARMA, INC. SEC Filing (Jul 13, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQbFdoZWR1NktZYllYc3RIWTBrOXZsdk5aT2g2U1VyN2x5bzYtbkM3b0Y2WXhVOVZINFNBaFlEcF85cXdBLWo3SFBaLUxEZHdaUW84c0RBTjRHc0czUFRwbU9UeWFsemJTZG9wQ2NjdE4xbWQ4ZmF3Q1lEd09jQ0xKVDhIbXJvbWtjUk9oNXFsdzdTNXNWTkZfcWU5QmNwd0ZaNm1GNQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:11:40+00:00", "published_display": "13 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] CRESCENT BIOPHARMA, INC. SEC Filing", "summary": "This article reports on an SEC filing (Form EFFECT) by CRESCENT BIOPHARMA, INC. (CBIO) which became effective on July 10, 2026. The filing is a Form S-3 (Shelf Registration) and has a neutral impact and sentiment according to StockTitan. The article also provides company overview", "url": "https://www.stocktitan.net/sec-filings/CBIO/effect-crescent-biopharma-inc-sec-filing-587c79f70b35.html", "source_name": "Stock Titan", "published_at": "2026-07-13T10:11:46", "published_display": "13 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Crescent Biopharma Inc (CBIO) Stock, Price, News, Quotes, Forecast and Insights | MSN Money", "summary": "This article provides stock information for Crescent Biopharma Inc (CBIO), including its current price, daily and 52-week ranges, open price, and previous close. It also lists key financial metrics such as market capitalization, shares outstanding, and EPS, indicating the stock i", "url": "https://www.msn.com/en-ae/money/stockdetails/fi-a1typ2?ocid=mailsignout", "source_name": "MSN", "published_at": "2026-07-11T13:40:14", "published_display": "11 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Crescent Biopharma, Inc. \u2013 NASDAQ:CBIO", "summary": "This article provides the \"Price to sales forward\" financial metric for Crescent Biopharma, Inc. (NASDAQ: CBIO). The content appears to be a stub or a section from a financial data platform, indicating the value and change of this specific financial ratio for the company. While t", "url": "https://www.tradingview.com/symbols/NASDAQ-CBIO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T12:40:31", "published_display": "07 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Crescent Biopharma, Inc. \u2013 NASDAQ:CBIO", "summary": "The article provides the enterprise value to EBITDA forward for Crescent Biopharma, Inc. (NASDAQ: CBIO) as presented on TradingView. It highlights that this financial metric and related data are sourced from ICE Data Services and FactSet, with SEC filings provided by Quartr. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-CBIO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T04:11:08", "published_display": "07 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Crescent Biopharma, Inc. \u2013 NASDAQ:CBIO", "summary": "The article discusses the \"Price to book forward\" metric for Crescent Biopharma, Inc. (NASDAQ: CBIO) as presented on TradingView. It appears to be a financial data point without further analysis or context within the provided snippet. The content primarily lists navigation and fo", "url": "https://www.tradingview.com/symbols/NASDAQ-CBIO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T16:11:50", "published_display": "06 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Crescent Biopharma, Inc. \u2013 NASDAQ:CBIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRlg0MjFmd2pKNFBtZG1VRjRSUHVOWFllaXRlNVp1Sm04MHJzWGFoc1U5NUlKRkFkMHRMQVNxNS1lRDhRNC1UYmxrSVBER0pmUXp4WGgxc1doTERRQTFJaXoyRS1hVEkzTjIzQ1J2RWh1S2xEUWRWbUhhSzFDeFpQQmR0UlZhdVNNaXFaTXpEY3pmenp0Z09CcmUxbWdfZG04QUVXNTdjRjRBaTQ?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T06:46:46+00:00", "published_display": "05 Jul 2026 06:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma files prospectus for $500M mixed shelf", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNMkJaMU1oemdRbUZQbjl4Tk1oQ3pfUjdrUXdNajRRMXZ1czB2aVR5V2RNZUlJaVZwR2d4N1hKYmo0NkxKTWlqenFIQ0duWDV2TjRtUkJnOHlsVE9EUlBzSmtTdl9VUjNKeGhGSWZpVi1TUmpZZklFTkxtSXFqSnJnSlJoUldQLWhuZzNHV2lJSHVqdDQxeTgzNGhtTUpMRTYzaV9ubDFrUEVnLTg?oc=5", "source_name": "scanx.trade", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Announces Grants of Inducement Awards", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/crescent-biopharma-announces-grants-inducement-201500650.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T20:15:00+00:00", "published_display": "26 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma awards 65,100 options to 3 new hires", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQbVVyRW4wNjM4TUs3VjNCUFNJeEVyb0cteE0yRGJXZzJDbktwQ3ZTZ1pQMjZmcjd4REM5Q19HdmFoeEptbHJKaURxZXZzeFBNVmhpTHdadjE2dFZ4aGxoWUZOY042MTh4RUdqd3EyeEJBc1p6dUdkQ1pqeE43SFByVW5aMVU5X1kyMjNBcE9CU0dlckJUd25QOEw2cXJDX1Y3VDJzc1dZZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tax-related insider share sale at Crescent Biopharma (CBIO) under Rule 10b5-1", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOOVRYNFlmVUpnVWlDdmVsTkRaRlYzZl9vNlBaVlNWYXlaSEtOdnh1aklXbHctZTZRSDh2Z0R3VnFFU0wyLUJRa2tvZjFIRkwwZVExcGtacFF5N1FiOGhBNDEtSFJ6WUNnOGdzejROVGZwX0pRcThYY2tNb0tGWmhRN0tDNk9fSU8xbWxSQmZuMlVTNjd4RjhNUDh1Sm1uQW96aE1ac29Pc0w0dFUtUy1wRS1uZkoxSW8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRESCENT BIOPHARMA (CBIO) CSO\u2019s 1,288-share sale covers RSU tax withholding", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPaEFnSkk4ZW9DSDFYZDBtWDhoX01NUHF2dDJ0enRVNWw0UjZZM1Vfam1UQmtOVUhkV2wyWGE0S2xkSUtKaFkxR0NDSmsyN01KMWNia2UtckU5aHFzSWt4OW42dThVV1hKSmFUazUzQzBIeEtDSmZKeElYdWtGUlJiWEJHY185S2ZYWURVakhiRkZkSGpHUG12RUxaWmNXMUw0ZFVFQVdZZFhqeGtrdi1PczZNY3QtQ3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRESCENT BIOPHARMA (CBIO) CMO auto-sells shares to cover RSU taxes", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOVlQ0MkJWWmU3UmhxNV9PenlmSUU4X0ZCdVdrblBmTDdkbGZxcE1YRngtTmlET19WZS00QWowMFpDY0tTM0RYVFZLU3A2YWV2ODNGZEhiMHZEMWgyTTZENGNMNzl5cVh2SnVieTBycE1tSFl3RWN1VjlneUxwUnlib0ZZTDlYYXo5SzBCSmxaRWNsMGp0M29PTkNxWHItN2RoNnVaX05rWk95dW9IejFkUU5WQzVyZlk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (CBIO) CEO\u2019s pre-planned tax sale covers RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOdkZGWkZuU1lydW9tbU1UelgyN0p5NDAzVE5qaXg4YWw4QVVrVzlVRTJTUG94dzdEVS1uMkNBcGpaXzd5djJGUWVkVU9nX0RMNHU2b21vOUhzMllINVBUSHRZRE1ZQTNWVEozMTNmNU5aYnA1YW9JdVgwVUtjU0VOQmtSdElWNHZtRWVXUnlUa2dyTFVxel9JenE2cU1aRm54RjdoUWZPc0ZmSEpTZkxuOGFNdkJPc1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma to Present at June Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/crescent-biopharma-present-june-investor-201500664.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T20:15:00+00:00", "published_display": "02 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Rings the Nasdaq Stock Market Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOQlNWRlpoUG93SDV1a2dzWkJwQjE4TExNUVU4Tk13aUxKQmZ5RVhET3dzYVpsNmpMZVpqQ2U1eUVTeFNmSGJBLUFCU2d5SmZ1QTZxWDVOWnViMS1yd3hkelo3ekEyeEJmb3hnVmNrWFQzYTZWNXVXclFZTWRHamtZcXBNQ1lfcTlCbHA0bVl6RF8?oc=5", "source_name": "Nasdaq", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Crescent Biopharma to Present at May Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/crescent-biopharma-present-may-investor-113000150.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T11:30:00+00:00", "published_display": "06 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/crescent-biopharma-reports-first-quarter-201500323.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T20:15:00+00:00", "published_display": "29 Apr 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Crescent Biopharma Grants Equity Inducement Awards to New Employees as Part of 2025 Incentive Plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNS0RwYnhXWXE2di1HZk1pdmY1MVRZZTUwdFkxRUVhSG1Od3pmMTdDVHl3MkhrcThoMWJDMEF6ajU0QmlUem1JSVhLdzhTZVRlRU9YYkJTSXhpRWNKc3VqUXRwdGY1TVkzd01JQXlUT0JvRUxPNVZoZE5vbVhvU3FTVmNnbU80OUZhcmdOSWc2UzhuMjZTLWtPYjNvQTVkWGJNdFRXZ3pSeUU5Y0hfbTZobk9WVm1nUVI3c281NFBiLUxWMHZZcVpiS1RxUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRESCENT BIOPHARMA, INC. ($CBIO) CEO & Director 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTVFMnJfTjN4NW9XdVF5bThNSW8zTmtUQWFzU2oxU244QzBWTnNRTU5aYkJreWhWQ09rSVNYcmRrQU9tSFZIREF5OW50dy1TTERXUXh6ZWxIN0N5Y19qVEw3dEc3aEQtMVJXTEp2ZkRkdW90MGFzQnI1WlR6QU1qQ2JJWFhWbEhKSnJMemNhYW5EVTVkajJzZVExTUhwYlk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Crescent Biopharma Stock Surges 86%, With A 7-Day Winning Spree", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQV09BbGpZclhid29hckFEMVBpZ1pOQUVENjhOelZIci0wa05WQ0xDdTJDeTE1cTc4bmtCc2ROazNHajUySzhFZkNJX1N1U2VJcHBtSUtFYlJuMl9zbmhOM0hDbmlYMDZRQ0stdjRRMEg2dTJicVBXcXdwcVZENzZJSkVZbnEyam5fR3RCaE1EOVJ0ZkNiZWpROU9vejVSekV5am1MdUJqRmhUOGZTZVZtMUFZc1NRakJEbzdaRDk3MA?oc=5", "source_name": "Trefis", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Crescent Biopharma (CBIO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5Ld3U3WW95OERHd1VKbUtJN0lla1lvWW05R2lKSk91ekE2Q3lHbjU1cmJYclk2N2hBTE55N3QxR1VyQ0twLWVoNnBUaE53Rnd4Zmt4cXJnbWY1UQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-16T00:01:16+00:00", "published_display": "16 Aug 2016 00:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Fairmount Funds holds 16.5% of Crescent Biopharma (CBIO) after July 2026 deal", "summary": "Fairmount Funds Management LLC and its affiliates, including Fairmount Healthcare Fund II L.P., now beneficially own 16.50% of Crescent Biopharma (CBIO), totaling 6,593,385 Ordinary Shares as of July 16, 2026. This increased stake follows the purchase of 853,450 Ordinary Shares a", "url": "https://www.stocktitan.net/sec-filings/CBIO/schedule-13d-a-crescent-biopharma-inc-amended-major-shareholder-repor-643066df58e0.html", "source_name": "Stock Titan", "published_at": "2026-07-21T07:41:01", "published_display": "21 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fairmount Healthcare Fund II LP acquires 853,450 Crescent Biopharma shares for $12.38 million", "summary": "Fairmount Healthcare Fund II LP has acquired 853,450 ordinary shares of Crescent Biopharma at $14.5 each, increasing its total stake to 3,601,316 shares. Additionally, the fund purchased 525,897 pre-funded warrants at the same price, bringing its warrant position to 2,294,037. To", "url": "https://www.bitget.com/amp/news/detail/12560605521763", "source_name": "Bitget", "published_at": "2026-07-21T02:09:44", "published_display": "21 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fairmount Funds' $12 Million Bet on Crescent Biopharma: A Strong Signal Amidst Volatility", "summary": "Fairmount Funds Management, a major stakeholder and director of Crescent Biopharma (CBIO), recently invested over", "url": "https://www.kavout.com/market-lens/fairmount-funds-12-million-bet-on-crescent-biopharma-a-strong-signal-amidst-volatility", "source_name": "Kavout | AI", "published_at": "2026-07-21T00:09:44", "published_display": "21 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider fund at Crescent Biopharma (NASDAQ: CBIO) buys 1.38M shares, warrants", "summary": "Fairmount Healthcare Fund II L.P., an entity linked to Crescent Biopharma (NASDAQ: CBIO), recently acquired 853,450 ordinary shares and 525,897 pre-funded warrants, totaling 1.38 million share equivalents. These transactions, executed on July 16, 2026, increased Fairmount's indir", "url": "https://www.stocktitan.net/sec-filings/CBIO/form-4-crescent-biopharma-inc-insider-trading-activity-86eeba4f21b9.html", "source_name": "Stock Titan", "published_at": "2026-07-20T21:41:01", "published_display": "20 Jul 2026 21:41", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgJBVV95cUxPRHNDSHFfV2xSMEE1Q01ZRm5DUGhtQ1hXanpEVTNUVThZWW5IRXd3VDJ0VlEwZHNTdmlmb0JUYVRYa0JUOVpOTjJ0dGlSdVE3dFdSNkhQeUZkYkRLYXJfY2dFNTBJUEs4MEwtYzFlRGp6a1pSeG1ldjhQOVFQVTZaTk9FRTd2SFN4akFXeWRqbFB3X25EYWVSOUFtSHduN1RBdnNGcHhNNl9LYkFSb1dpMUNNYWhVZ3VZQmYwV0dNMVhxellicU5BSktudkJJMGQwbkxvSVdhbnB2U3M1VnB3TGJUTmIyM081UEtrclJMaGhpRUdVck4yTFlWcVpHUGxHT2dBV3RXVFNmZEpQMVlFZ0hnZk1YeHhRWUFlYk5zMURCam5vcHc?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-17T10:42:00+00:00", "published_display": "17 Jul 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (CBIO) Jefferies Global Healthcare Conference 2026 Summary", "summary": "Crescent Biopharma (CBIO) presented at the Jefferies Global Healthcare Conference 2026, highlighting strong clinical data for HARMONi-6, validating PD-1/VEGF bispecifics, and discussing critical trial design strategies. The company provided updates on its pipeline, focusing on CR", "url": "https://quartr.com/events/crescent-biopharma-inc-cbio-jefferies-global-healthcare-conference-2026_FVuhh8IK", "source_name": "Quartr", "published_at": "2026-07-17T09:40:02", "published_display": "17 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares", "summary": "Crescent Biopharma has announced the closing of its public offering, which included 3,000,000 ordinary shares and pre-funded warrants to purchase 3,450,000 ordinary shares, at a price of $4.00 per share or $3.9999 per pre-funded warrant. The offering also saw the full exercise of", "url": "https://www.moomoo.com/news/post/73095343/press-release-crescent-biopharma-announces-closing-of-public-offering-of?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-17T03:40:02", "published_display": "17 Jul 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma closes $143.7 million public offering By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOZWhCRUNFOGlhdWdjaEgxZldUeVNYaWlCSTVyMUN0VVNfR3c2SVNFTWJpRTdkV3VwcmxWSUJNN0RXZEx5eXFraF9VSDJ0eU5admdicjdsUTZ4OGxxRDdKaEVLVnNZcVRjZUM0S0FPMkFSQ2FVU21NWU1aQnFnS29FN3dmLXNHMmg5MEdqYVRJM1BEb2ppdGJDY2RRR1laU1RUYWs4bHJZUDZuQ0ZjcS0yT1A0b3VJZw?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-17T00:12:58+00:00", "published_display": "17 Jul 2026 00:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Closes $143.7 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/crescent-biopharma-closes-143-7-202247362.html", "source_name": "MT Newswires", "published_at": "2026-07-16T20:22:47+00:00", "published_display": "16 Jul 2026 20:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (CBIO) Proxy filing Summary", "summary": "Crescent Biopharma (CBIO) has released a summary of its proxy filing ahead of its Annual General Meeting on June 2, 2026. Key proposals include the election of two Class II directors, ratification of PricewaterhouseCoopers LLP as auditor, and advisory votes on executive compensat", "url": "https://quartr.com/events/crescent-biopharma-inc-cbio-proxy-filing_FVuhhxfq", "source_name": "Quartr", "published_at": "2026-07-16T20:10:50", "published_display": "16 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Offering Closes With 9.4M Shares, Warrants", "summary": "Crescent Biopharma (CBIO) announced the closing of its underwritten public offering, which included 9,387,896 ordinary shares and pre-funded warrants for up to 525,897 ordinary shares. The offering, priced at $14.50 per ordinary share and $14.499 per pre-funded warrant, generated", "url": "https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-closing-of-public-offering-of-ordinary-v6nqa6hv9ivn.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:10:13", "published_display": "16 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares", "summary": "Crescent Biopharma, Inc. announced the closing of its public offering, generating approximately $143.7 million in gross proceeds. The offering included 9,387,896 ordinary shares and pre-funded warrants for up to 525,897 ordinary shares, with the underwriters fully exercising thei", "url": "https://www.globenewswire.com/news-release/2026/07/16/3328781/0/en/Crescent-Biopharma-Announces-Closing-of-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html", "source_name": "GlobeNewswire", "published_at": "2026-07-16T16:01:00", "published_display": "16 Jul 2026 16:01", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (CBIO) Bank of America Global Healthcare Conference 2026 Summary", "summary": "Crescent Biopharma (CBIO) presented at the Bank of America Global Healthcare Conference 2026, outlining its strategic vision in oncology with a focus on a next-gen IO bispecific (CR-001) and an ADC portfolio. The company initiated clinical dosing for CR-001 and CR-003 in early 20", "url": "https://quartr.com/events/crescent-biopharma-cbio-bank-of-america-global-healthcare-conference-2026_FVuhhoQQ", "source_name": "Quartr", "published_at": "2026-07-16T15:10:51", "published_display": "16 Jul 2026 15:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 424B5 CRESCENT BIOPHARMA, INC.", "summary": "Crescent Biopharma, Inc. is offering 8,094,793 ordinary shares and 525,897 pre-funded warrants, with an aim to raise approximately $115.9 million in net proceeds to fund clinical development of its product candidates CR-001, CR-002, and CR-003, as well as for research and develop", "url": "https://www.streetinsider.com/SEC+Filings/Form+424B5+CRESCENT+BIOPHARMA%2C+INC./26774795.html", "source_name": "StreetInsider", "published_at": "2026-07-16T14:42:00", "published_display": "16 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (Nasdaq: CBIO) prices $125.0 million stock and warrant sale", "summary": "Crescent Biopharma (Nasdaq: CBIO) has priced a public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $125.0 million in gross proceeds. The offering includes 8,094,793 ordinary shares at $14.50 each and 525,897 pre-funded warrants at $14.499 eac", "url": "https://www.stocktitan.net/sec-filings/CBIO/8-k-crescent-biopharma-inc-reports-material-event-490590889f2f.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:42:00", "published_display": "15 Jul 2026 20:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Prices $125 Million Public Offering of Ordinary Shares and Pre-Funded Warrants", "summary": "Crescent Biopharma announced the pricing of a public offering expected to raise approximately $125 million by selling 8,094,793 ordinary shares and 525,897 pre-funded warrants. The ordinary shares are priced at $14.50 each, and the pre-funded warrants at $14.499, with the offerin", "url": "https://www.quiverquant.com/news/Crescent+Biopharma+Prices+$125+Million+Public+Offering+of+Ordinary+Shares+and+Pre-Funded+Warrants", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T15:10:51", "published_display": "15 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Prices $125 Million Common, Warrant Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/crescent-biopharma-prices-125-million-075209963.html", "source_name": "MT Newswires", "published_at": "2026-07-15T07:52:09+00:00", "published_display": "15 Jul 2026 07:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma prices $125M public offering at $14.50/share", "summary": "Crescent Biopharma Inc. (NASDAQ:CBIO) has priced an underwritten public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $125 million. The shares are priced at $14.50, and the offering is expected to close soon, with major financial institutions ", "url": "https://www.investing.com/news/company-news/crescent-biopharma-prices-125m-public-offering-at-1450share-93CH-4792104", "source_name": "Investing.com", "published_at": "2026-07-15T04:12:52", "published_display": "15 Jul 2026 04:12", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Selling All Shares, Prefunded Warrants to Be Sold in Offering >CBIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQVS00UVBhdXNDVUxsaGs1NUhFeVFoOGMxVUJPSFJRV0dwT3lNQkpNbk5scFFoR2VTYW02bFBXdG03MFZjdzVaYy1yb3RlaHJZUUFXQ1dfRjJfekJWOHBLbzlGazY3WHZBVXF2UHZNSG1ja0dfQ1p6UDRWUXNfVG9vbzRBRlRwdlkyeEVqTEo2akVFczdNN1pTOGtHTFY2ZEtxQ0pJYXI3NGlNNFE4MGc?oc=5", "source_name": "Moomoo", "published_at": "2026-07-15T02:16:00+00:00", "published_display": "15 Jul 2026 02:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Also Offering Certain Investors Prefunded Warrants to Buy 525,897 Shares >CBIO", "summary": "Crescent Biopharma has announced an offering to certain investors of prefunded warrants to purchase 525,897 shares. This financial move allows these investors to effectively buy shares at a predetermined price in the future. The offering is likely aimed at raising capital or opti", "url": "https://www.moomoo.com/news/post/72970756/crescent-biopharma-also-offering-certain-investors-prefunded-warrants-to-buy?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-15T02:39:34", "published_display": "15 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants", "summary": "Crescent Biopharma has announced the pricing of its underwritten public offering, which includes 8,094,793 ordinary shares at $14.50 per share and pre-funded warrants for up to 525,897 ordinary shares at $14.499 per warrant. The offering is expected to generate approximately $125", "url": "https://www.globenewswire.com/news-release/2026/07/15/3327429/0/en/Crescent-Biopharma-Announces-Pricing-of-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T01:47:56", "published_display": "15 Jul 2026 01:47", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Sets $14.50 Price for 8.1M Shares", "summary": "Crescent Biopharma (Nasdaq: CBIO) announced the pricing of an underwritten public offering of 8,094,793 ordinary shares at $14.50 per share and 525,897 pre-funded warrants at $14.499 each, expecting to raise approximately $125 million in gross proceeds. The offering is anticipate", "url": "https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-pricing-of-public-offering-of-ordinary-03p42p5b41ft.html", "source_name": "Stock Titan", "published_at": "2026-07-15T01:47:56", "published_display": "15 Jul 2026 01:47", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Launches Offering of Common Shares, Warrants", "summary": "Crescent Biopharma Inc. (NasdaqCM:CBIO) has announced an offering of common shares and warrants. This news was published on July 14, 2026, at 4:24 pm EDT. The company specializes in developing therapies for cancer patients, with lead programs including a PD-1 x VEGF bispecific an", "url": "https://www.marketscreener.com/news/crescent-biopharma-launches-offering-of-common-shares-warrants-ce7f5edddd88f524", "source_name": "marketscreener.com", "published_at": "2026-07-14T20:24:00", "published_display": "14 Jul 2026 20:24", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Crescent Biopharma, Inc. \u2013 NASDAQ:CBIO", "summary": "The article focuses on the \"Price to earnings forward\" metric for Crescent Biopharma, Inc. (NASDAQ: CBIO). It appears to be a truncated financial data page from TradingView, providing basic company and stock market information without detailed financial figures. The content prima", "url": "https://www.tradingview.com/symbols/NASDAQ-CBIO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T19:47:56", "published_display": "14 Jul 2026 19:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants", "summary": "Crescent Biopharma has announced a proposed underwritten public offering of its ordinary shares or pre-funded warrants to purchase ordinary shares. The company also intends to grant underwriters a 30-day option to purchase an additional 15% of ordinary shares. Jefferies, TD Cowen", "url": "https://www.globenewswire.com/news-release/2026/07/14/3327240/0/en/Crescent-Biopharma-Announces-Proposed-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T19:47:56", "published_display": "14 Jul 2026 19:47", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Offering Lets Investors Choose Shares or Warrants", "summary": "Crescent Biopharma (Nasdaq: CBIO) has initiated an underwritten public offering, allowing investors to purchase either ordinary shares or pre-funded warrants. The company reserves a 30-day option for underwriters to acquire an additional 15% of ordinary shares. This offering is p", "url": "https://www.stocktitan.net/news/CBIO/crescent-biopharma-announces-proposed-public-offering-of-ordinary-fy05y47xgxit.html", "source_name": "Stock Titan", "published_at": "2026-07-14T19:47:56", "published_display": "14 Jul 2026 19:47", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (NASDAQ: CBIO) reports $171.6M preliminary cash as of June 30, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxONC1tdm1PTW5HaFE1SzA1dks5bXFhbkk2ZEFrRmN5Vm4zQ3BYVG1IZXRZemhHZ2RBTTVPZlVPVk41X2x6N3ZSNUJFanFjZDVMWEFjWnZxNDJ0bVg1dWFaNndnS1AxSnp0VEdYMTVvOU9YbmJZSGExLUlxeXNlV3FLOWstaXBlUy1aR1pQci16ZkFscG1wZjdWcFM3azVPeWNHZUxMNUVtSFFXc1REU04teQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T07:00:00+00:00", "published_display": "14 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRESCENT BIOPHARMA, INC. SEC Filing (Jul 13, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQbFdoZWR1NktZYllYc3RIWTBrOXZsdk5aT2g2U1VyN2x5bzYtbkM3b0Y2WXhVOVZINFNBaFlEcF85cXdBLWo3SFBaLUxEZHdaUW84c0RBTjRHc0czUFRwbU9UeWFsemJTZG9wQ2NjdE4xbWQ4ZmF3Q1lEd09jQ0xKVDhIbXJvbWtjUk9oNXFsdzdTNXNWTkZfcWU5QmNwd0ZaNm1GNQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-13T10:11:40+00:00", "published_display": "13 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] CRESCENT BIOPHARMA, INC. SEC Filing", "summary": "This article reports on an SEC filing (Form EFFECT) by CRESCENT BIOPHARMA, INC. (CBIO) which became effective on July 10, 2026. The filing is a Form S-3 (Shelf Registration) and has a neutral impact and sentiment according to StockTitan. The article also provides company overview", "url": "https://www.stocktitan.net/sec-filings/CBIO/effect-crescent-biopharma-inc-sec-filing-587c79f70b35.html", "source_name": "Stock Titan", "published_at": "2026-07-13T10:11:46", "published_display": "13 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Inc (CBIO) Stock, Price, News, Quotes, Forecast and Insights | MSN Money", "summary": "This article provides stock information for Crescent Biopharma Inc (CBIO), including its current price, daily and 52-week ranges, open price, and previous close. It also lists key financial metrics such as market capitalization, shares outstanding, and EPS, indicating the stock i", "url": "https://www.msn.com/en-ae/money/stockdetails/fi-a1typ2?ocid=mailsignout", "source_name": "MSN", "published_at": "2026-07-11T13:40:14", "published_display": "11 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Crescent Biopharma, Inc. \u2013 NASDAQ:CBIO", "summary": "This article provides the \"Price to sales forward\" financial metric for Crescent Biopharma, Inc. (NASDAQ: CBIO). The content appears to be a stub or a section from a financial data platform, indicating the value and change of this specific financial ratio for the company. While t", "url": "https://www.tradingview.com/symbols/NASDAQ-CBIO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T12:40:31", "published_display": "07 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Crescent Biopharma, Inc. \u2013 NASDAQ:CBIO", "summary": "The article provides the enterprise value to EBITDA forward for Crescent Biopharma, Inc. (NASDAQ: CBIO) as presented on TradingView. It highlights that this financial metric and related data are sourced from ICE Data Services and FactSet, with SEC filings provided by Quartr. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-CBIO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T04:11:08", "published_display": "07 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Crescent Biopharma, Inc. \u2013 NASDAQ:CBIO", "summary": "The article discusses the \"Price to book forward\" metric for Crescent Biopharma, Inc. (NASDAQ: CBIO) as presented on TradingView. It appears to be a financial data point without further analysis or context within the provided snippet. The content primarily lists navigation and fo", "url": "https://www.tradingview.com/symbols/NASDAQ-CBIO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T16:11:50", "published_display": "06 Jul 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Crescent Biopharma, Inc. \u2013 NASDAQ:CBIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRlg0MjFmd2pKNFBtZG1VRjRSUHVOWFllaXRlNVp1Sm04MHJzWGFoc1U5NUlKRkFkMHRMQVNxNS1lRDhRNC1UYmxrSVBER0pmUXp4WGgxc1doTERRQTFJaXoyRS1hVEkzTjIzQ1J2RWh1S2xEUWRWbUhhSzFDeFpQQmR0UlZhdVNNaXFaTXpEY3pmenp0Z09CcmUxbWdfZG04QUVXNTdjRjRBaTQ?oc=5", "source_name": "TradingView", "published_at": "2026-07-05T06:46:46+00:00", "published_display": "05 Jul 2026 06:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma files prospectus for $500M mixed shelf", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNMkJaMU1oemdRbUZQbjl4Tk1oQ3pfUjdrUXdNajRRMXZ1czB2aVR5V2RNZUlJaVZwR2d4N1hKYmo0NkxKTWlqenFIQ0duWDV2TjRtUkJnOHlsVE9EUlBzSmtTdl9VUjNKeGhGSWZpVi1TUmpZZklFTkxtSXFqSnJnSlJoUldQLWhuZzNHV2lJSHVqdDQxeTgzNGhtTUpMRTYzaV9ubDFrUEVnLTg?oc=5", "source_name": "scanx.trade", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Announces Grants of Inducement Awards", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/crescent-biopharma-announces-grants-inducement-201500650.html", "source_name": "GlobeNewswire", "published_at": "2026-06-26T20:15:00+00:00", "published_display": "26 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma awards 65,100 options to 3 new hires", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQbVVyRW4wNjM4TUs3VjNCUFNJeEVyb0cteE0yRGJXZzJDbktwQ3ZTZ1pQMjZmcjd4REM5Q19HdmFoeEptbHJKaURxZXZzeFBNVmhpTHdadjE2dFZ4aGxoWUZOY042MTh4RUdqd3EyeEJBc1p6dUdkQ1pqeE43SFByVW5aMVU5X1kyMjNBcE9CU0dlckJUd25QOEw2cXJDX1Y3VDJzc1dZZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tax-related insider share sale at Crescent Biopharma (CBIO) under Rule 10b5-1", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOOVRYNFlmVUpnVWlDdmVsTkRaRlYzZl9vNlBaVlNWYXlaSEtOdnh1aklXbHctZTZRSDh2Z0R3VnFFU0wyLUJRa2tvZjFIRkwwZVExcGtacFF5N1FiOGhBNDEtSFJ6WUNnOGdzejROVGZwX0pRcThYY2tNb0tGWmhRN0tDNk9fSU8xbWxSQmZuMlVTNjd4RjhNUDh1Sm1uQW96aE1ac29Pc0w0dFUtUy1wRS1uZkoxSW8?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRESCENT BIOPHARMA (CBIO) CSO\u2019s 1,288-share sale covers RSU tax withholding", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPaEFnSkk4ZW9DSDFYZDBtWDhoX01NUHF2dDJ0enRVNWw0UjZZM1Vfam1UQmtOVUhkV2wyWGE0S2xkSUtKaFkxR0NDSmsyN01KMWNia2UtckU5aHFzSWt4OW42dThVV1hKSmFUazUzQzBIeEtDSmZKeElYdWtGUlJiWEJHY185S2ZYWURVakhiRkZkSGpHUG12RUxaWmNXMUw0ZFVFQVdZZFhqeGtrdi1PczZNY3QtQ3c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRESCENT BIOPHARMA (CBIO) CMO auto-sells shares to cover RSU taxes", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOVlQ0MkJWWmU3UmhxNV9PenlmSUU4X0ZCdVdrblBmTDdkbGZxcE1YRngtTmlET19WZS00QWowMFpDY0tTM0RYVFZLU3A2YWV2ODNGZEhiMHZEMWgyTTZENGNMNzl5cVh2SnVieTBycE1tSFl3RWN1VjlneUxwUnlib0ZZTDlYYXo5SzBCSmxaRWNsMGp0M29PTkNxWHItN2RoNnVaX05rWk95dW9IejFkUU5WQzVyZlk?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (CBIO) CEO\u2019s pre-planned tax sale covers RSU vesting", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOdkZGWkZuU1lydW9tbU1UelgyN0p5NDAzVE5qaXg4YWw4QVVrVzlVRTJTUG94dzdEVS1uMkNBcGpaXzd5djJGUWVkVU9nX0RMNHU2b21vOUhzMllINVBUSHRZRE1ZQTNWVEozMTNmNU5aYnA1YW9JdVgwVUtjU0VOQmtSdElWNHZtRWVXUnlUa2dyTFVxel9JenE2cU1aRm54RjdoUWZPc0ZmSEpTZkxuOGFNdkJPc1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma to Present at June Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/crescent-biopharma-present-june-investor-201500664.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T20:15:00+00:00", "published_display": "02 Jun 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Rings the Nasdaq Stock Market Closing Bell", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOQlNWRlpoUG93SDV1a2dzWkJwQjE4TExNUVU4Tk13aUxKQmZ5RVhET3dzYVpsNmpMZVpqQ2U1eUVTeFNmSGJBLUFCU2d5SmZ1QTZxWDVOWnViMS1yd3hkelo3ekEyeEJmb3hnVmNrWFQzYTZWNXVXclFZTWRHamtZcXBNQ1lfcTlCbHA0bVl6RF8?oc=5", "source_name": "Nasdaq", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma to Present at May Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/crescent-biopharma-present-may-investor-113000150.html", "source_name": "GlobeNewswire", "published_at": "2026-05-06T11:30:00+00:00", "published_display": "06 May 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/crescent-biopharma-reports-first-quarter-201500323.html", "source_name": "GlobeNewswire", "published_at": "2026-04-29T20:15:00+00:00", "published_display": "29 Apr 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Grants Equity Inducement Awards to New Employees as Part of 2025 Incentive Plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNS0RwYnhXWXE2di1HZk1pdmY1MVRZZTUwdFkxRUVhSG1Od3pmMTdDVHl3MkhrcThoMWJDMEF6ajU0QmlUem1JSVhLdzhTZVRlRU9YYkJTSXhpRWNKc3VqUXRwdGY1TVkzd01JQXlUT0JvRUxPNVZoZE5vbVhvU3FTVmNnbU80OUZhcmdOSWc2UzhuMjZTLWtPYjNvQTVkWGJNdFRXZ3pSeUU5Y0hfbTZobk9WVm1nUVI3c281NFBiLUxWMHZZcVpiS1RxUQ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRESCENT BIOPHARMA, INC. ($CBIO) CEO & Director 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTVFMnJfTjN4NW9XdVF5bThNSW8zTmtUQWFzU2oxU244QzBWTnNRTU5aYkJreWhWQ09rSVNYcmRrQU9tSFZIREF5OW50dy1TTERXUXh6ZWxIN0N5Y19qVEw3dEc3aEQtMVJXTEp2ZkRkdW90MGFzQnI1WlR6QU1qQ2JJWFhWbEhKSnJMemNhYW5EVTVkajJzZVExTUhwYlk?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma Stock Surges 86%, With A 7-Day Winning Spree", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQV09BbGpZclhid29hckFEMVBpZ1pOQUVENjhOelZIci0wa05WQ0xDdTJDeTE1cTc4bmtCc2ROazNHajUySzhFZkNJX1N1U2VJcHBtSUtFYlJuMl9zbmhOM0hDbmlYMDZRQ0stdjRRMEg2dTJicVBXcXdwcVZENzZJSkVZbnEyam5fR3RCaE1EOVJ0ZkNiZWpROU9vejVSekV5am1MdUJqRmhUOGZTZVZtMUFZc1NRakJEbzdaRDk3MA?oc=5", "source_name": "Trefis", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crescent Biopharma (CBIO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5Ld3U3WW95OERHd1VKbUtJN0lla1lvWW05R2lKSk91ekE2Q3lHbjU1cmJYclk2N2hBTE55N3QxR1VyQ0twLWVoNnBUaE53Rnd4Zmt4cXJnbWY1UQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-16T00:01:16+00:00", "published_display": "16 Aug 2016 00:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 58, "sentiment_summary": {"positive": 11, "negative": 7, "neutral": 40, "score": 52, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 87, "events": [{"event": "general", "label": "Market update", "weight": 23.65, "count": 43}, {"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 14.75, "latest_week": "2026-07-17", "one_week_move": -14.9, "four_week_move": -16.6, "twelve_week_move": -40.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.32296, "market_dynamics_buy_signal": false, "relative_strength": -7.611394, "fair_value_gap": 1.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "positive", "expectation_probability": 59.4737, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-14.9% over one week, -16.6% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "GlobeNewswire", "count": 7}, {"label": "Market source", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "Quartr", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "Quiver Quantitative", "count": 3}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 43}, {"label": "Earnings", "count": 12}, {"label": "Deals and strategy", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "87/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-14.9% over one week, -16.6% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Fairmount Funds holds 16.5% of Crescent Biopharma (CBIO) after July 2026 deal"}], "updated_at": "2026-07-23T00:58:28.564502+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}